Samtidig indgift af INTELENCE og lægemidler, som primært metaboliseres af CYP3A4, kan resultere i en reduktion af plasmakoncentrationen af disse lægemidler, hvilket kan reducere eller forkorte deres terapeutiske virkning.
Co-administration of INTELENCE with medicinal products primarily metabolised by CYP3A4 may result in decreased plasma concentrations of such medicinal products, which could decrease or shorten their therapeutic effects.